The MRPL34 Knockout Huh-7 Cell Line is a precisely engineered human hepatocellular carcinoma model featuring CRISPR/Cas9-mediated disruption of the MRPL34 gene, which encodes a structural component of the mitochondrial large ribosomal subunit. This targeted gene disruption creates a stable loss-of-function system for dissecting the roles of mitochondrial translation in cellular metabolism and disease pathogenesis. The knockout cell line enables researchers to directly interrogate the consequences of impaired mitoribosome function within an endogenously relevant hepatic carcinoma background, providing a robust platform for mechanistic and pharmacological studies.
The Huh-7 host cell line is a well-differentiated human hepatocellular carcinoma model with epithelial morphology, widely utilized for investigating hepatitis C virus replication, liver cancer biology, and hepatocyte metabolism. Derived from a liver tumor, Huh-7 cells retain many hepatic metabolic features and are particularly suited for studies of mitochondrial function in the context of hepatocellular carcinoma. This background facilitates exploration of how MRPL34 loss influences cancer cell bioenergetics and stress responses, leveraging the cell line’s established roles in liver disease research.
MRPL34 is an integral component of the 39S large subunit of the mitochondrial ribosome, where it participates in the translation of mtDNA-encoded polypeptides essential for oxidative phosphorylation (OXPHOS) complex assembly. Knockout of MRPL34 disrupts mitochondrial protein synthesis, leading to reduced expression of downstream targets such as MT-ND1 and MT-CO1, which are core subunits of respiratory chain complexes I and IV, respectively. The gene is transcriptionally regulated by upstream factors including TFAM, NRF1, NRF2, and the coactivator PGC-1??, linking mitochondrial biogenesis programs to translational output. Additionally, MRPL34 functions in concert with interacting partners like other MRPL proteins, mitoribosome assembly factors, and translation factors mtIF2, mtIF3, and mtEF-Tu, underscoring its cooperative role in the mitoribosomal machinery.
In the Huh-7 hepatocellular carcinoma context, MRPL34 knockout induces metabolic reprogramming by impairing the synthesis of OXPHOS subunits, thereby forcing reliance on glycolytic pathways and potentially sensitizing cells to metabolic stress. This model is particularly valuable for examining the interplay between mitochondrial dysfunction and cancer metabolism, as well as for modeling mitochondrial diseases linked to ribosomal defects. The epithelial hepatic origin of Huh-7 cells allows for the study of liver-specific mitochondrial pathologies, offering insights into how compromised mitochondrial translation contributes to tumorigenesis and drug resistance mechanisms.
Researchers can employ this knockout cell line in diverse applications, including mitochondrial disease modeling, cancer metabolism studies, drug screening for mitochondrial dysfunction, and investigation of mitochondrial ribosomal pathologies. Representative assays include western blotting to confirm MRPL34 ablation, RT-qPCR for mitochondrial gene expression changes, oxygen consumption rate measurements to assess respiratory capacity, blue-native PAGE for OXPHOS complex assembly, cell viability testing under metabolic stress, and immunofluorescence to visualize mitochondrial morphology alterations. For further details and ordering information, please contact Ascent Research.
